Novo Nordisk's ZEUS Failure: The Inflammation Thesis Just Got Repriced

Novo Nordisk spent years running a large-scale trial testing one idea about heart disease. This morning that idea broke — and it took two companies down with it that never ran a trial.

Meanwhile Regeneron, Bristol Myers and AbbVie all beat in the same session, and one of those numbers is Humira-scale. It's been a loud Friday. Let's get into it.

Welcome to The Pharma Closeout for Friday, July thirty-first. I'm Alex Mercer.

And I'm Maya Patel.

Ziltivekimab missed its primary endpoint in ZEUS. Novo down ten percent. But look at the tape underneath it — BioAge Labs down sixty percent. Monte Rosa Therapeutics sharply lower. Neither of them had anything read out today.

Which is the whole story. Novo got this asset when it bought Corvidia, and ZEUS was the field's cleanest test of residual inflammatory risk — a large trial enrolling patients with heart disease, chronic kidney disease, and elevated hsCRP. That is the friendliest population the hypothesis was ever going to get. If it fails there, you can't blame the design.

And here's the line that's going to get argued about all weekend. Per Novo's own statement, the drug did lower inflammation markers. The pharmacology worked. It just didn't turn into events.

OK, but I'd push hard on treating that as a consolation. Lowering hsCRP was never in doubt — anti-IL-6 antibodies do that reliably. The bet was that the marker was causal, not just along for the ride. Novo confirmed the pharmacology and disconfirmed the thesis in the same readout. That's worse than a drug that simply doesn't work, because there's no dose argument left. No duration argument. You hit the target and the patients didn't benefit.

I'd take that correction — it sharpens where this lands rather than softening it. If the marker moved and the outcomes didn't, every program priced off that same causal chain just got repriced by somebody else's data.

Which is precisely what a sixty percent move in BioAge is. Nobody read out. Investors just decided the read-through was real and priced it inside a session. BioPharma Dive framed it as casting doubt on the whole idea of treating cardiovascular disease by targeting inflammation.

That's the part that should worry Novo beyond the stock. This lands on top of the CagriSema disappointment and the amycretin repositioning, while they're in a straight fight with Lilly for the obesity franchise. The pattern is starting to look like a pipeline problem, not a run of bad luck.

I'd separate those, actually. Obesity and cardiovascular inflammation are different scientific bets that happened to fail in the same eighteen months. The market won't separate them — but a diligence team should.

Fair. The competitive read: if you're running strategy on any cardiovascular asset whose value case rests on residual inflammatory risk, your board conversation changed this morning. Not because your data changed — because the comparator everyone was waiting on came back negative. Diligence gets slower, partnering terms get worse, and the burden of proof is now yours.

And the open question is what Novo does with the subgroups. In a trial this size there will be a responder analysis that looks encouraging, and the temptation is enormous. Whether they present it as hypothesis-generating or as a path forward tells you how much of the kidney strategy was resting on this. We said yesterday we'd watch for anything further from Novo before the week closed. As of this session, nothing.

Shifting to the deal and earnings side — and the tape did most of the talking today. Regeneron: a quarter a share against a Zacks consensus of ten. Shares up six point two percent. Reuters puts it on eczema — Dupixent. We flagged this one as it was landing yesterday; today is the market's verdict.

The thing I'd read next to that beat is BioPharma Dive's roundup line — Sanofi saying it wants to rebuild trust with Regeneron. When a partner has to say that out loud about a franchise this size, the Dupixent economics are being renegotiated in public.

Bristol Myers beat too. Two dollars and four cents against a consensus of a quarter. Stock up two point eight percent.

On a beat that size? That's a shrug.

It is. And that's the tell.

Nobody's paying for the quarter. Endpoints has called 2026 a make-or-break year for BMS against the Revlimid and Eliquis exclusivity losses, and a two point eight percent move says the market has already modeled the hole and doesn't think one good quarter fills it.

Also worth noting on the commercial side — Madrigal, on July thirtieth: Rezdiffra net sales of three hundred sixty-four point three million, up seventy-one percent year over year. More than forty-nine thousand patients on drug as of June thirtieth, more than double a year ago. We've had this launch on the watch list since the spring, and it is compounding.

The line I'd underline in that release isn't the sales number. It's MGL-2086 — an oral GLP-1 they describe as an orforglipron derivative — dosed in Phase 1 in June, explicitly to combine with Rezdiffra. Madrigal is telling you it does not believe a THR-beta agonist wins MASH on its own. That's a franchise attacking its own moat before anyone else does, which is the only time that decision is cheap.

And a smaller one that fits the same theme — IMPACT Therapeutics licensed senaparib, its PARP inhibitor, to Pharmanovia across Europe, the Middle East, North Africa, Australia and New Zealand. Total consideration reaching a substantial sum, plus tiered royalties reaching into the double digits, per the announcement. Dozens of countries.

Which is the standard shape now for a China-origin oncology asset reaching the West — you don't build the commercial infrastructure, you rent someone's. The EMA filing was accepted last August with approval expected in the back half of this year, so the partner is buying a near-term launch, not a science project. The read for anyone holding an approved asset in one geography: the licensing market is pricing regulatory proximity, not novelty.

On the regulatory and commercial-execution side, the number of the day belongs to AbbVie. Skyrizi did five and a half billion dollars in the quarter, and per Fierce Pharma that matches Humira's best-ever quarter. AbbVie raised full-year sales guidance on it. We touched this yesterday as it broke — the guidance raise is what's new today.

And Endpoints put the competitive line right in the headline: Skyrizi's momentum is defying J&J's Icotyde. That's an oral IL-23 peptide pointed directly at this franchise.

This is where I'd slow everything down, because I think the wrong lesson is being drawn. An oral doesn't take share from an injectable inside a quarter. It takes it at the contracting cycle — and the first cycle where Icotyde can actually be positioned against Skyrizi on a formulary hasn't turned over yet. So this quarter is evidence that AbbVie's contracting held. It is not evidence that the oral threat was overstated. Those are two different claims and only one of them has support today.

So you'd hold the confetti.

I'd hold it until a full formulary cycle turns. AbbVie also picked up a pair of EU approvals for Rinvoq on the thirtieth, which is the other half of the same story — they're widening the immunology base while the IL-23 fight is still theoretical.

Which is the right sequencing if you believe the fight is coming.

And that's the implication for anyone modeling this. The post-Humira question is answered on the revenue line and reopened on the durability line. AbbVie has proven it can replace the molecule. What it has not yet proven is that it can defend the replacement against a modality it doesn't sell.

Looking ahead — first item is whether Novo puts any further detail behind ZEUS, and whether the inflammation cohort in cardiovascular stays repriced or bounces on Monday. Those two things are related and they won't resolve at the same speed.

I'd add the Regeneron–Sanofi language. "Rebuild trust" tends to precede a restructured arrangement, not a goodwill press release. If those terms move, the Dupixent economics behind today's beat look different a year from now.

And on Madrigal — don't track the next sales print, track whether the oral combination program stays on schedule. THR-beta plus an oral GLP-1 is the likely shape of MASH in 2028, and whoever lands there first writes the standard everyone else has to beat.

And that is your Pharma Closeout for Friday, July thirty-first — a ZEUS failure that took three companies down with it, Skyrizi hitting Humira-scale, Regeneron and Bristol Myers both beating into very different receptions, and Rezdiffra compounding. This industry does not do quiet Fridays. Follow wherever you listen — the Week in Review lands Sunday.

It really doesn't. Go enjoy your weekend — I'll be reading those ZEUS subgroups the second Novo puts them anywhere near a slide.